Literature DB >> 19020425

Development of an accurate oscillometric blood pressure device for low resource settings.

Annemarie de Greeff1, Hannah Nathan, Nina Stafford, Bing Liu, Andrew H Shennan.   

Abstract

OBJECTIVE: To assess and develop an accurate blood pressure measurement device for use in low resource settings and by untrained staff, according to the World Health Organisation guidelines.
METHODS: Ninety-nine adults were recruited to validate the device according to the International Protocol of the European Society of Hypertension. All participants provided written informed consent. Patients with an arrhythmia or unclear Korotkoff sounds were excluded. Nine sequential same-arm measurements were taken from each participant alternating between the test device and mercury sphygmomanometry. Differences between the test device and observers were evaluated according to the criteria of the International Protocol and the Association for the Advancement of Medical Instrumentation.
RESULTS: The device failed the first assessment of the oscillometric function and required modification to both the deflation rate and the algorithm to fulfil the International Protocol criteria. It then achieved an acceptable mean difference of -0.7 (4.7) mmHg for systolic and -2.0 (4.6) mmHg for diastolic pressure (oscillometric function) and -1.9 (3.8) mmHg and -0.9 (3.3) mmHg for systolic and diastolic pressures, respectively (auscultatory function).
CONCLUSION: The Microlife 3AS1-2 is a semi-automated upper arm device with features consistent with low resource requirements. We successfully developed this device for accurate blood pressure measurement in adults according to the International Protocol, through adjustment of the deflation rate and algorithm. The accuracy and user-friendly design of this low-cost device makes it a highly valuable monitor in clinical practice, particularly in low resource settings and for use by untrained staff.

Entities:  

Mesh:

Year:  2008        PMID: 19020425     DOI: 10.1097/MBP.0b013e32830fd07c

Source DB:  PubMed          Journal:  Blood Press Monit        ISSN: 1359-5237            Impact factor:   1.444


  16 in total

1.  Reverse innovation in maternal health.

Authors:  Tabassum Firoz; Prestige Tatenda Makanga; Hannah L Nathan; Beth Payne; Laura A Magee
Journal:  Obstet Med       Date:  2017-05-16

Review 2.  Point-of-care diagnostics to improve maternal and neonatal health in low-resource settings.

Authors:  Catherine E Majors; Chelsey A Smith; Mary E Natoli; Kathryn A Kundrod; Rebecca Richards-Kortum
Journal:  Lab Chip       Date:  2017-10-11       Impact factor: 6.799

3.  Vital Sign Prediction of Adverse Maternal Outcomes in Women with Hypovolemic Shock: The Role of Shock Index.

Authors:  Alison M El Ayadi; Hannah L Nathan; Paul T Seed; Elizabeth A Butrick; Natasha L Hezelgrave; Andrew H Shennan; Suellen Miller
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

4.  The CRADLE vital signs alert: qualitative evaluation of a novel device designed for use in pregnancy by healthcare workers in low-resource settings.

Authors:  Hannah L Nathan; Helena Boene; Khatia Munguambe; Esperança Sevene; David Akeju; Olalekan O Adetoro; Umesh Charanthimath; Mrutyunjaya B Bellad; Annemarie de Greeff; John Anthony; David R Hall; Wilhelm Steyn; Marianne Vidler; Peter von Dadelszen; Lucy C Chappell; Jane Sandall; Andrew H Shennan
Journal:  Reprod Health       Date:  2018-01-05       Impact factor: 3.223

5.  Evaluation of a novel vital sign device to reduce maternal mortality and morbidity in low-resource settings: a mixed method feasibility study for the CRADLE-3 trial.

Authors:  Nicola Vousden; Elodie Lawley; Hannah L Nathan; Paul T Seed; Adrian Brown; Tafadzwa Muchengwa; Umesh Charantimath; Mrutyunjaya Bellad; Muchabayiwa Francis Gidiri; Shivaprasad Goudar; Lucy C Chappell; Jane Sandall; Andrew H Shennan
Journal:  BMC Pregnancy Childbirth       Date:  2018-04-27       Impact factor: 3.007

6.  Early warning system hypertension thresholds to predict adverse outcomes in pre-eclampsia: A prospective cohort study.

Authors:  Hannah L Nathan; Paul T Seed; Natasha L Hezelgrave; Annemarie De Greeff; Elodie Lawley; John Anthony; David R Hall; Wilhelm Steyn; Lucy C Chappell; Andrew H Shennan
Journal:  Pregnancy Hypertens       Date:  2017-11-21       Impact factor: 2.899

7.  Development and evaluation of a novel Vital Signs Alert device for use in pregnancy in low-resource settings.

Authors:  Hannah L Nathan; Nicola Vousden; Elodie Lawley; Annemarie de Greeff; Natasha L Hezelgrave; Nicola Sloan; Nina Tanna; Shivaprasad S Goudar; Muchabayiwa F Gidiri; Jane Sandall; Lucy C Chappell; Andrew H Shennan
Journal:  BMJ Innov       Date:  2018-09-19

8.  The feasibility of task-sharing the identification, emergency treatment, and referral for women with pre-eclampsia by community health workers in India.

Authors:  Umesh Charanthimath; Marianne Vidler; Geetanjali Katageri; Umesh Ramadurg; Chandrashekhar Karadiguddi; Avinash Kavi; Anjali Joshi; Geetanjali Mungarwadi; Sheshidhar Bannale; Sangamesh Rakaraddi; Diane Sawchuck; Rahat Qureshi; Sumedha Sharma; Beth A Payne; Peter von Dadelszen; Richard Derman; Laura A Magee; Shivaprasad Goudar; Ashalata Mallapur; Mrutyunjaya Bellad; Zulfiqar Bhutta; Sheela Naik; Anis Mulla; Namdev Kamle; Vaibhav Dhamanekar; Sharla K Drebit; Chirag Kariya; Tang Lee; Jing Li; Mansun Lui; Asif R Khowaja; Domena K Tu; Amit Revankar
Journal:  Reprod Health       Date:  2018-06-22       Impact factor: 3.223

9.  Cost effectiveness of medical devices to diagnose pre-eclampsia in low-resource settings.

Authors:  Zoë M McLaren; Alana Sharp; John P Hessburg; Amir Sabet Sarvestani; Ethan Parker; James Akazili; Timothy R B Johnson; Kathleen H Sienko
Journal:  Dev Eng       Date:  2017-07-03

10.  Evaluation of a novel device for the management of high blood pressure and shock in pregnancy in low-resource settings: study protocol for a stepped-wedge cluster-randomised controlled trial (CRADLE-3 trial).

Authors:  Hannah L Nathan; Kate Duhig; Nicola Vousden; Elodie Lawley; Paul T Seed; Jane Sandall; Mrutyunjaya B Bellad; Adrian C Brown; Lucy C Chappell; Shivaprasad S Goudar; Muchabayiwa F Gidiri; Andrew H Shennan
Journal:  Trials       Date:  2018-03-27       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.